Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novavax, Inc. stock logo
NVAX
Novavax
$6.61
+4.9%
$6.78
$5.01
$17.81
$1.02B2.696.31 million shs5.97 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novavax, Inc. stock logo
NVAX
Novavax
-1.10%-0.16%-14.75%+5.00%-50.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Novavax, Inc. stock logo
NVAX
Novavax
4.5045 of 5 stars
3.12.00.04.71.40.83.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$17.00157.19% Upside

Current Analyst Ratings Breakdown

Latest NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.57N/AN/A($3.89) per share-1.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.4982.630.0638.14%-115.51%29.99%8/14/2025 (Estimated)

Latest NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03

Institutional Ownership

CompanyInstitutional Ownership
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable

Recent News About These Companies

Novavax Faces Challenges Amid Stock Decline
Novavax: New Vaccine, Same Old Story - Still A Sell

New MarketBeat Followers Over Time

Media Sentiment Over Time

Novavax stock logo

Novavax NASDAQ:NVAX

$6.61 +0.31 (+4.92%)
Closing price 04:00 PM Eastern
Extended Trading
$6.64 +0.02 (+0.38%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.